Please use this identifier to cite or link to this item:
Title: The HOME Core outcome set for clinical trials of atopic dermatitis
Authors: Williams, Hywel C.
Schmitt, Jochen
Thomas, Kim S.
Spuls, Phyllis I.
Simpson, Eric L.
Apfelbacher, Christian
Chalmers, Joanne R.
Furue, Masutaka
Katoh, Norito
Gerbens, Louise A. A.
Leshem, Yael A.
Howells, Laura
Singh, Jasvinder A.
Boers, Maarten
Keywords: Science::Medicine
Issue Date: 2022
Source: Williams, H. C., Schmitt, J., Thomas, K. S., Spuls, P. I., Simpson, E. L., Apfelbacher, C., Chalmers, J. R., Furue, M., Katoh, N., Gerbens, L. A. A., Leshem, Y. A., Howells, L., Singh, J. A. & Boers, M. (2022). The HOME Core outcome set for clinical trials of atopic dermatitis. Journal of Allergy and Clinical Immunology, 149(6), 1899-1911.
Journal: Journal of Allergy and Clinical Immunology
Abstract: Core outcome sets are critically important outcomes that should be measured in clinical trials. Their absence in atopic dermatitis is a form of research waste and impedes combining evidence to inform patient care. Here, we articulate the rationale for core outcome sets in atopic dermatitis and review the work of the international Harmonising Outcome Measures for Eczema group from its inception in Munich, 2010. We describe core domain determination (what should be measured), to instrument selection (how domains should be measured), culminating in the complete core outcome measurement set in Tokyo, 2019. Using a "road map," Harmonising Outcome Measures for Eczema includes diverse research methods including Delphi and nominal group techniques informed by systematic reviews of properties of candidate instruments. The 4 domains and recommended instruments for including in all clinical trials of atopic dermatitis are patient symptoms, measured by Patient-Oriented Eczema Measure and peak Numerical Rating Scale 11 for itch intensity over 24 hours, clinical signs measured using the Eczema Area and Severity Index, quality of life measured by the Dermatology Life Quality Index series for adults, children, and infants, and long-term control measured by either Recap of atopic eczema or Atopic Dermatitis Control Tool.
ISSN: 0091-6749
DOI: 10.1016/j.jaci.2022.03.017
Rights: © 2022 The Authors. Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology. This is an open access article under the CC BY license (
Fulltext Permission: open
Fulltext Availability: With Fulltext
Appears in Collections:LKCMedicine Journal Articles

Files in This Item:
File Description SizeFormat 
PIIS009167492200389X (1).pdf1.18 MBAdobe PDFView/Open

Citations 20

Updated on Dec 3, 2022

Web of ScienceTM
Citations 50

Updated on Nov 26, 2022

Page view(s)

Updated on Dec 3, 2022


Updated on Dec 3, 2022

Google ScholarTM




Items in DR-NTU are protected by copyright, with all rights reserved, unless otherwise indicated.